Apimeds Pharmaceuticals US, Inc.
APUS
$2.24
$0.209.80%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 120.77% | 49.52% | 96.50% | 1,148.98% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 164.45% | 42.06% | 70.58% | 512.18% | -- |
| Operating Income | -164.45% | -42.06% | -70.58% | -512.18% | -- |
| Income Before Tax | -160.64% | -48.17% | -78.73% | -476.73% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.64% | -48.17% | -78.73% | -476.73% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.64% | -48.17% | -78.73% | -476.73% | -- |
| EBIT | -164.45% | -42.06% | -70.58% | -512.18% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -86.35% | -17.36% | -25.11% | -217.61% | -- |
| Normalized Basic EPS | -86.50% | -17.26% | -24.91% | -217.12% | -- |
| EPS Diluted | -86.35% | -17.36% | -25.11% | -217.61% | -- |
| Normalized Diluted EPS | -86.50% | -17.26% | -24.91% | -217.12% | -- |
| Average Basic Shares Outstanding | 28.57% | 40.82% | 71.89% | 89.53% | -- |
| Average Diluted Shares Outstanding | 28.57% | 40.82% | 71.89% | 89.53% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |